OXiGENE is a biopharmaceutical company whose mission is finding and developing new and improved therapeutics that can deliver significant medical benefits to patients with cancer and sight-threatening eye diseases and conditions.

Monday, December 12, 2011
OXiGENE and Azanta A/S Establish Partnership to Provide ZYBRESTAT(TM) for ATC in Europe on Named Patient, Compassionate Use Basis

Wednesday, December 7, 2011
OXiGENE Presents Data From FAVOR Study of ZYBRESTAT in PCV